Posted inBiotechnology
Heart Failure and Obesity: New Treatment Strategies Unveiled
Heart failure (HF) has emerged as a global health crisis, with its prevalence soaring in tandem with the rise in…
Posted inBiotechnology
Astrocytic Ca2+ Protects Synapses During Motor Learning
Astrocytes, once considered mere support cells in the brain, have rapidly ascended to the forefront of neuroscience due to their…
Posted inBiotechnology
Enhanced Nanostructured Anodes Boost Lithium-Ion Battery Performance
Recent advancements in lithium-ion battery technology continue to revolutionize the field of energy storage, a key aspect of the global…
Posted inBiotechnology
Nobiletin Nanoparticles Reverse Sleep Deprivation Cognitive Decline
In an era marked by ever-increasing demands for cognitive performance and mental resilience, the shadow of sleep deprivation continues to…
Posted inBiotechnology
Robust Single-Pixel Imaging Tackles Real-World Degradations
In a groundbreaking advancement for optical imaging technology, researchers have unveiled a novel method to drastically improve the resilience of…
Posted inBiotechnology
‘Not here to refine the status quo’: Excellergy emerges with $70M, plans to redefine allergy therapeutics
Excellergy has emerged with $70 million and an investigative drug class in its portfolio, part of its ambitious mission to…
Posted inBiotechnology
AI Predicts Growth Risks in Preterm Infants
In a groundbreaking advancement that could reshape neonatal care, researchers have employed artificial intelligence to predict extrauterine growth restriction (EUGR)…
Posted inBiotechnology
LTBP4 Variants Linked to Severe Pediatric Sepsis
In a groundbreaking study published in Pediatric Research, scientists have unveiled a critical genetic link that could revolutionize our understanding…
Posted inBiotechnology
Programmable Promoter Editing Enables Precise Transgene Control
In the rapidly evolving landscape of synthetic biology, the ability to precisely regulate gene expression remains one of the most…
Posted inBiotechnology
Tvardi’s STAT3 inhibitor flunks phase 2 IPF trial amid high dropout rates
Tvardi Therapeutics has failed its first big test as a public company. Months after joining the Nasdaq, the biotech has reported…